STAAR Surgical defends merger process amid activist criticism
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
December 11, 2025 9:47 AM ESTActivist Investors Have Twisted Facts Regarding STAARs Engagement with a Potentially Interested Party During Go-Shop Process
The Potentially Interested Party Reached Out on Day 21 of 30-Day Go-Shop Process and Refused to Sign an NDA Even without a Standstill
Broadwood Partners and Yunqi Capital Continue to Distort the Truth for Their Own Benefit
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL) for vision... More
